Goldline Pharmaceutical IPO

Listed SME
Min Investment
₹2,58,000
6000 Shares
Min Investment
₹2,58,000 · 6000 Shares
Price Band ₹41–43
Lot Size 3000 shares
Issue Size ₹12 Cr
Listed At ₹59.75 +39%
Subscribed 840.57×
Listed On BSE SME

Goldline Pharmaceutical IPO Listing Day Performance

Goldline Pharmaceutical listed on BSE SME on 19 May 2026 at ₹59.75, a 38.95% premium over the issue price of ₹43. A retail investor allotted the minimum application of 6,000 shares (2 lots) gained ₹1,00,500 at the listing price.

Issue price
₹43
upper band
Listing price
₹59.75
pre-open auction
Listing gain
+38.95%
+₹16.75 per share
Profit per application
+₹1,00,500
6,000 shares

GMP vs actual listing

Last GMP before listing₹15 (+34.9%)
GMP-implied listing₹58
Actual listing₹59.75
Difference+₹1.75 (+3.0%)

Demand going into listing

Subscribed overall840.57×
QIB180.22×
NII1662.35×
Retail880.68×
Listing price = opening price from the exchange's pre-open call auction on listing day. Watch live price

Market Sentiment

Grey Market Premium What is GMP?
+₹15
+34.9% ▼ ₹2 since last update
Est. listing ₹58
Upper price ₹43
GMP range ₹0 – ₹25
08 May · ₹0 18 May · ₹15
Updated 18 May, 2:48 pm IST Unofficial grey-market data
GMP estimate ₹58
Actual listing ₹59.75
Listed above the GMP estimate by ₹1.75 (+3.0%)
Subscription Status
QIB
180.22x
NII
1,662.35x
bNII (>10L)
1,662.35x
sNII (2-10L)
1,662.35x
Retail
880.68x
Total
840.57x
Updated: May 14, 2026 4:58 pm IST
Analysis Score 79 / 100
Data: 80%
GMP Score · 44% weight 68
Subscription Score · 38% weight 100
Financial Health · 19% weight 66
Weighted average of the parts above; updates as GMP and subscription change. not investment advice.

IPO Details

Price Band₹41–43 per equity share
Face Value₹10 Per Equity Share
Total Issue Size ₹12.00 crore
Fresh IssueEntire issue — no offer for sale, so all proceeds go to the company
Issue TypeBook build Issue
Lead Manager Cumulative Capital Pvt. Ltd.
Registrar Bigshare Services Pvt. Ltd.
Listing atBSE SME
BSE Code544759
Listing Price₹59.75
Listing Gain+38.95%

Day-wise Subscription (times subscribed)

QIB
NII
Retail
Total
Each panel has its own scale.
Category Day 1 Day 2 Day 3
QIB 1.31x 1.31x 180.22x
NII 18.07x 108.19x 1,662.35x
bNII > ₹10L 24.46x 146.48x 1,662.35x
sNII 2-10L 24.46x 146.48x 1,662.35x
Retail 34.07x 139.51x 880.68x
Total 20.79x 93.19x 840.57x

Market Lot Size

Category Lots Shares Amount (₹)
Retail Minimum 2 6,000 ₹2,58,000
Retail Maximum 2 6,000 ₹2,58,000
S-HNI Minimum 3 9,000 ₹3,87,000
S-HNI Maximum 7 21,000 ₹9,03,000
B-HNI Minimum 8 24,000 ₹10,32,000

IPO Reservation

QIB 21.1% NII 15.2% Retail 35.1% Anchor 28.6%
Category Shares Offered Shares %
QIB5,40,00021.08%
NII (HNI)3,90,00015.22%
bNII > ₹10L2,60,00010.15%
sNII < ₹10L1,30,0005.07%
Retail9,00,00035.13%
Anchor7,32,00028.57%
Total25,62,000

Financial Analysis

Financial Data

ROE
35.84%
ROCE
38.46%
Debt/Equity
1.50
NAV/Share
₹12.39
Revenue Growth
19.05%
Profit Margin
10.09%

Financial Performance

2025 vs 2024 Revenue +19.0% Profit (PAT) +56.4% Total Assets +14.6%
Metric 2023 2024 2025
Revenue 19.85 23.57 28.06
Expense 19.45 21.04 24.20
Profit (PAT) 0.26 1.81 2.83
Total Assets 19.39 22.93 26.28
Values in Crores (₹)

Peer Comparison

Company EPS P/E Market Cap (Cr)
Mono Pharmacare Limited 1.75 12.57 10
Chandra Bhagat Pharma Limited 1.14 37.73 3
Peer median P/E 25.2x across 2 listed peers

Promoters & Holding Pattern

Promoters: Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal

Shareholding No. of Shares Holding %
Promoter Holding Pre Issue 69,00,000 79.70%

Strengths & Risks

Strengths
  • Heavily oversubscribed — 840.6x overall (so far).
  • Strong institutional (QIB) demand — 180.2x.
  • Revenue grew 19% in the latest reported year.
  • Solid profit margin — 10.1%.
  • Strong return on equity — 36%.
Risks & Concerns
  • Elevated leverage — debt/equity of 1.50.
  • Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.

From this issue's live data. Not investment advice — read the RHP.

Company Information

Goldline Pharmaceutical at a glance

From the company's description: “Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline.”

Goldline Pharmaceutical is raising ₹12 crore through an IPO on the BSE SME. All of it is a fresh issue: there is no offer for sale, so every rupee raised goes to the company rather than to selling shareholders. Main stated uses of the fresh money: Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company (₹8.9 crore).

Revenue went from ₹19.85 crore in 2023 to ₹28.06 crore in 2025, up 41% over 2 years. Profit after tax went from ₹0.26 crore to ₹2.83 crore, a net margin of 10% in the latest year.

Debt stands at 1.5 times equity.

Written from the issue's offer-document figures shown on this page. Not investment advice.

Company Contact Information

Goldline Pharmaceutical Ltd., 103, F-1, Leela Apartment, Shilpa HSG Society,, Near Saptagiri Nagar, Shanidham,, Narendra Nagar,, Nagpur, Maharashtra, 440015

Objects of the Issue

Purpose Amount (Cr)
Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company 8.90
General Corporate Purpose -

Resources & Documents

Anchor Investors

Anchor Bidding Date
May 11, 2026
Shares Offered to Anchors
7,32,000

Goldline Pharmaceutical IPO - Quick Take

Goldline Pharmaceutical has set a price band of Rs 41–Rs 43 per share for an issue size of Rs 12 crore. The stock listed with a 38.95% gain versus its issue price on May 19, 2026.

The issue is promoted by Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal with Cumulative Capital Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company (Rs 9 crore) and general Corporate Purpose.

On fundamentals, the company is posting revenue growth of 19.1%, a profit margin of 10.1%, return on equity of 35.8% in its most recent reported period. Listed peers in this segment include Mono Pharmacare Limited (P/E 12.57x, market cap Rs 10 crore) and Chandra Bhagat Pharma Limited (P/E 37.73x, market cap Rs 3 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.

On our data-signal score, the combined signals for this issue currently read strong — the composite picture tilts positive, though not without some caveats. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.

Goldline Pharmaceutical IPO: Lead Manager & Registrar Track Record

How the firm running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Goldline Pharmaceutical itself, so they describe what came before it.

SME IPOs, last 12 months
  • Goldline Pharmaceutical listed at +39% on day one; the median of 193 listings was +1.5% (better than 84% of them).
  • Subscribed 841x against a median of 3.98x across 192 issues (higher than 100%).
  • Average listing-day move across all 194 SME listings we track: +11.6%.
Lead manager and registrar record on other IPOs we track
Firm Other IPOs Listed at / above issue Avg move Median
Cumulative Capital Pvt. Ltd. Lead manager 3 2 MB · 1 SME 100% 3 of 3 +9.1% +10%
Bigshare Services Pvt. Ltd. Registrar 61 19 MB · 42 SME 67% 41 of 61 Check allotment →
Recent listings managed by Cumulative Capital Pvt. Ltd. (3)

Best: Mehul Telecom +10.2% · Weakest: Hexagon Nutrition +7.2%

IPOListedListing-day move
Veegaland Developers 18 Sep 2026 +10%
Hexagon Nutrition 12 Jun 2026 +7.2%
Mehul Telecom 24 Apr 2026 +10.2%
What a lead manager does

A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.

What a registrar does

Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.

Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.

Frequently Asked Questions

Goldline Pharmaceutical listed at Rs 59.75 on 19 May 2026, against an issue price of Rs 43 — a 38.95% premium.

+38.95% at the listing price — Rs 16.75 per share, or Rs 1,00,500 on the minimum retail application of 6,000 shares.

The price band of Goldline Pharmaceutical IPO is Rs 41 to Rs 43 per share. Face value is Rs 10 per share.

The total issue size of Goldline Pharmaceutical IPO is Rs 12 crore, comprising fresh issue of Rs 12 crore.

The lot size of Goldline Pharmaceutical IPO is 3,000 shares. The minimum application is 2 lots (6,000 shares), requiring an investment of Rs 2,58,000.

Goldline Pharmaceutical IPO opens for subscription on May 12, 2026 and closes on May 14, 2026. Anchor investor bidding is scheduled for May 11, 2026.

The expected allotment date for Goldline Pharmaceutical IPO is May 15, 2026. Refunds for unsuccessful applicants are expected on May 18, 2026.

Goldline Pharmaceutical IPO is scheduled to list on May 19, 2026 on BSE. BSE script code: 544759, ISIN: –.

The last GMP (Grey Market Premium) recorded for Goldline Pharmaceutical IPO before listing was +Rs 15 (+34.9% over issue price). The shares actually listed at Rs 59.75 (+38.95% versus the issue price). GMP only estimates the listing price and stops mattering once the shares trade.

Goldline Pharmaceutical IPO was subscribed 840.57 times overall by the close of bidding — retail at 880.68x, QIB at 180.22x, NII at 1,662.35x.

Based on the final retail subscription of 880.68x for Goldline Pharmaceutical IPO, the estimated retail allotment probability is approximately 0.13%. This is a low probability — approximately 1 out of every 100 retail applications may receive allotment.

The registrar for Goldline Pharmaceutical IPO is Bigshare Services Pvt. Ltd. After the allotment date, you can check your allotment status on the registrar's official website by entering your PAN, application number, or demat account details. Allotment status is also available on the BSE and NSE websites.

The book running lead manager(s) for Goldline Pharmaceutical IPO are Cumulative Capital Pvt. Ltd.

The promoter(s) of Goldline Pharmaceutical are Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal.

Goldline Pharmaceutical IPO GMP — What It Means

Its last GMP before listing was 34.9%. Of the 34 SME IPOs we have tracked with a final GMP of 25% or more, 34 listed above, 0 flat and 0 below the issue price; Goldline Pharmaceutical listed 39% above its issue price.

See the full Goldline Pharmaceutical GMP history and trend, or learn how grey market premium works and how reliable it is.

Related IPO

Same sector or same stage as Goldline Pharmaceutical
Side by side: GMP, subscription, valuation, financials and listing performance.
0 Comments

No comments yet. Be the first to share your opinion!

GMPUpdate